What if we would have watched it for six months? Like, I possibly couldn’t be here talking to you and have lived my life six ...

Novartis submitted data to the US Food and Drug Administration from the PSMAfore study seeking to expand the treatment's ...

LaShae Rolle shares her journey of being diagnosed with a rare breast cancer at the age of 26, making her a part of the less ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Pertuzumab (Perjeta) treats HER2-positive early breast cancer, usually in combination with trastuzumab and chemotherapy. It’s FDA-approved for neoadjuvant and adjuvant treatment. Neoadjuvant use ...

Breast cancer treatment has evolved in recent years with a growing number of hormone therapies, targeted drugs, and immunotherapies supporting more traditional approaches, like surgery, radiation, and ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

In the adorable photos, Isabella showed off her growing hair, which fans have been celebrating ever since she completed her last round of chemotherapy to treat her medulloblastoma—a rare form of ...